BioSpace News Archive

Novotech, the leading Asia Pacific centred biotech CRO has commissioned GlobalData to report on the evolving FDA approval processes for biotechs in Asia Pacific, Europe, and US, including typical impediments to success.

Gritstone bio, Inc. announced multiple presentations at the 33rd European Congress of Clinical Microbiology and Infectious Diseases, taking place April 15-18, 2023 in Copenhagen, Denmark.

Perfuse Therapeutics announced that the US Food and Drug Administration has cleared the Investigational New Drug application for a Phase 1/2a clinical study of PER-001 Intravitreal Implant in patients with glaucoma.

TransCode Therapeutics, Inc. announced that its previously announced sale of Series A Convertible Preferred Stock for an aggregate purchase price of $500,000 will not be consummated after the proposed purchaser advised the Company that it was not prepared to complete the transaction on the terms set forth in the Stock Purchase Agreement signed by the investor.

InflaRx N.V. (Nasdaq: IFRX) today announced that Gohibic (vilobelimab), a first-in-class monoclonal anti-human complement factor C5a antibody, has been granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the treatment of coronavirus disease 19 (COVID-19) in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation (IMV), or extracorporeal membrane oxygenation (ECMO).

Namida Lab, a global pioneering tear-based cancer screening, unveiled Auria®, the groundbreaking at-home biological breast cancer screening test, at the New Technology Showcase during the 32nd Annual Interdisciplinary Breast Center Conference (NCoBC) in Las Vegas.

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) today announced that management will present at the Diamond Equity Research Emerging Growth Invitational virtual investor conference taking place Wednesday, April 5th.

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced that it will report first quarter 2023 financial results on Thursday, April 27, 2023, before the market opens.

The Canadian Food Inspection Agency and the Public Health Agency of Canada issued the following joint statement.

Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2023 following the close of market on Tuesday, April 25, 2023.